Increasing system-wide implementation of opioid prescribing guidelines in primary care: findings from a non-randomized stepped-wedge quality improvement project.


Journal

BMC family practice
ISSN: 1471-2296
Titre abrégé: BMC Fam Pract
Pays: England
ID NLM: 100967792

Informations de publication

Date de publication:
28 11 2020
Historique:
received: 12 12 2019
accepted: 15 11 2020
entrez: 29 11 2020
pubmed: 30 11 2020
medline: 25 9 2021
Statut: epublish

Résumé

Clinician utilization of practice guidelines can reduce inappropriate opioid prescribing and harm in chronic non-cancer pain; yet, implementation of "opioid guidelines" is subpar. We hypothesized that a multi-component quality improvement (QI) augmentation of "routine" system-level implementation efforts would increase clinician adherence to the opioid guideline-driven policy recommendations. Opioid policy was implemented system-wide in 26 primary care clinics. A convenience sample of 9 clinics received the QI augmentation (one-hour academic detailing; 2 online educational modules; 4-6 monthly one-hour practice facilitation sessions) in this non-randomized stepped-wedge QI project. The QI participants were volunteer clinic staff. The target patient population was adults with chronic non-cancer pain treated with long-term opioids. The outcomes included the clinic-level percentage of target patients with a current treatment agreement (primary outcome), rates of opioid-benzodiazepine co-prescribing, urine drug testing, depression and opioid misuse risk screening, and prescription drug monitoring database check; additional measures included daily morphine-equivalent dose (MED), and the percentages of all target patients and patients prescribed ≥90 mg/day MED. T-test, mixed-regression and stepped-wedge-based analyses evaluated the QI impact, with significance and effect size assessed with two-tailed p < 0.05, 95% confidence intervals and/or Cohen's d. Two-hundred-fifteen QI participants, a subset of clinical staff, received at least one QI component; 1255 patients in the QI and 1632 patients in the 17 comparison clinics were prescribed long-term opioids. At baseline, more QI than comparison clinic patients were screened for depression (8.1% vs 1.1%, p = 0.019) and prescribed ≥90 mg/day MED (23.0% vs 15.5%, p = 0.038). The stepped-wedge analysis did not show statistically significant changes in outcomes in the QI clinics, when accounting for the comparison clinics' trends. The Cohen's d values favored the QI clinics in all outcomes except opioid-benzodiazepine co-prescribing. Subgroup analysis showed that patients prescribed ≥90 mg/day MED in the QI compared to comparison clinics improved urine drug screening rates (38.8% vs 19.1%, p = 0.02), but not other outcomes (p ≥ 0.05). Augmenting routine policy implementation with targeted QI intervention, delivered to volunteer clinic staff, did not additionally improve clinic-level, opioid guideline-concordant care metrics. However, the observed effect sizes suggested this approach may be effective, especially in higher-risk patients, if broadly implemented. Not applicable.

Sections du résumé

BACKGROUND
Clinician utilization of practice guidelines can reduce inappropriate opioid prescribing and harm in chronic non-cancer pain; yet, implementation of "opioid guidelines" is subpar. We hypothesized that a multi-component quality improvement (QI) augmentation of "routine" system-level implementation efforts would increase clinician adherence to the opioid guideline-driven policy recommendations.
METHODS
Opioid policy was implemented system-wide in 26 primary care clinics. A convenience sample of 9 clinics received the QI augmentation (one-hour academic detailing; 2 online educational modules; 4-6 monthly one-hour practice facilitation sessions) in this non-randomized stepped-wedge QI project. The QI participants were volunteer clinic staff. The target patient population was adults with chronic non-cancer pain treated with long-term opioids. The outcomes included the clinic-level percentage of target patients with a current treatment agreement (primary outcome), rates of opioid-benzodiazepine co-prescribing, urine drug testing, depression and opioid misuse risk screening, and prescription drug monitoring database check; additional measures included daily morphine-equivalent dose (MED), and the percentages of all target patients and patients prescribed ≥90 mg/day MED. T-test, mixed-regression and stepped-wedge-based analyses evaluated the QI impact, with significance and effect size assessed with two-tailed p < 0.05, 95% confidence intervals and/or Cohen's d.
RESULTS
Two-hundred-fifteen QI participants, a subset of clinical staff, received at least one QI component; 1255 patients in the QI and 1632 patients in the 17 comparison clinics were prescribed long-term opioids. At baseline, more QI than comparison clinic patients were screened for depression (8.1% vs 1.1%, p = 0.019) and prescribed ≥90 mg/day MED (23.0% vs 15.5%, p = 0.038). The stepped-wedge analysis did not show statistically significant changes in outcomes in the QI clinics, when accounting for the comparison clinics' trends. The Cohen's d values favored the QI clinics in all outcomes except opioid-benzodiazepine co-prescribing. Subgroup analysis showed that patients prescribed ≥90 mg/day MED in the QI compared to comparison clinics improved urine drug screening rates (38.8% vs 19.1%, p = 0.02), but not other outcomes (p ≥ 0.05).
CONCLUSIONS
Augmenting routine policy implementation with targeted QI intervention, delivered to volunteer clinic staff, did not additionally improve clinic-level, opioid guideline-concordant care metrics. However, the observed effect sizes suggested this approach may be effective, especially in higher-risk patients, if broadly implemented.
TRIAL REGISTRATION
Not applicable.

Identifiants

pubmed: 33248458
doi: 10.1186/s12875-020-01320-9
pii: 10.1186/s12875-020-01320-9
pmc: PMC7700706
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

245

Subventions

Organisme : Pfizer
ID : 16213567
Pays : International

Références

Jt Comm J Qual Patient Saf. 2015 Oct;41(10):474-9
pubmed: 26404077
Implement Sci. 2018 Jan 25;13(1):21
pubmed: 29370813
J Pain. 2009 Feb;10(2):113-30
pubmed: 19187889
J Pain. 2006 Sep;7(9):671-81
pubmed: 16942953
Pain Physician. 2012 Jul;15(3 Suppl):S67-116
pubmed: 22786449
Ann Intern Med. 2014 Jan 7;160(1):38-47
pubmed: 24217469
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
Pain Med. 2011 Jun;12 Suppl 2:S73-6
pubmed: 21668760
Ann Emerg Med. 2013 Sep;62(3):237-40
pubmed: 23374416
MMWR Recomm Rep. 2016 Mar 18;65(1):1-49
pubmed: 26987082
Am J Prev Med. 2015 Sep;49(3):409-13
pubmed: 25896191
JAMA Psychiatry. 2019 Feb 1;76(2):208-216
pubmed: 30516809
Am J Ind Med. 2012 Apr;55(4):325-31
pubmed: 22213274
Pain Physician. 2012 Jul;15(3 Suppl):S1-65
pubmed: 22786448
Health Technol Assess. 2004 Feb;8(6):iii-iv, 1-72
pubmed: 14960256
Medicine (Baltimore). 2016 Aug;95(35):e4760
pubmed: 27583928
BMC Health Serv Res. 2018 Jun 5;18(1):415
pubmed: 29871625
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Med Care. 2003 Nov;41(11):1284-92
pubmed: 14583691
J Gen Intern Med. 2018 Sep;33(9):1512-1519
pubmed: 29948815
Health Psychol. 2004 Sep;23(5):443-51
pubmed: 15367063

Auteurs

Aleksandra E Zgierska (AE)

Departments of Family and Community Medicine, Public Health Sciences, and Anesthesiology and Perioperative Medicine, Penn State College of Medicine, 500 University Drive, PA, 17033, Hershey, USA. azgierska@pennstatehealth.psu.edu.

James M Robinson (JM)

Center for Health Systems Research and Analysis, University of Wisconsin-Madison, 1109C WARF Building, 610 Walnut Street, Madison, WI, 53726, USA.

Robert P Lennon (RP)

Department of Family and Community Medicine, Penn State College of Medicine, 500 University Drive, Hershey, PA, 17033, USA.

Paul D Smith (PD)

Department of Family Medicine and Community Health, Wisconsin Research and Education Network (WREN), University of Wisconsin-Madison, School of Medicine and Public Health, 1100 Delaplaine Court, Madison, WI, 53715, USA.

Kate Nisbet (K)

Interstate Postgraduate Medical Association, P.O. Box 5474, Madison, WI, 53705, USA.

Mary W Ales (MW)

Interstate Postgraduate Medical Association, P.O. Box 5474, Madison, WI, 53705, USA.

Deanne Boss (D)

Department of Family Medicine and Community Health, Wisconsin Research and Education Network (WREN), University of Wisconsin-Madison, School of Medicine and Public Health, 1100 Delaplaine Court, Madison, WI, 53715, USA.

Wen-Jan Tuan (WJ)

Department of Family Medicine and Community Health, University of Wisconsin-Madison, School of Medicine and Public Health, 1100 Delaplaine Court, Madison, WI, 53715, USA.

Regina M Vidaver (RM)

Department of Family Medicine and Community Health, Wisconsin Research and Education Network (WREN), University of Wisconsin-Madison, School of Medicine and Public Health, 1100 Delaplaine Court, Madison, WI, 53715, USA.

David L Hahn (DL)

Department of Family Medicine and Community Health, Wisconsin Research and Education Network (WREN), University of Wisconsin-Madison, School of Medicine and Public Health, 1100 Delaplaine Court, Madison, WI, 53715, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH